Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brivaracetam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivaracetam SCHEMBL22446812 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL13596590 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL563918 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL563970 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL122081 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL564055 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL2408675 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| Brivaracetam SCHEMBL563666 | 1.00 | CA1 (0.49) | CA1CA2LMNACA12CA3 | |
| SCHEMBL563677 | 0.93 | LMNA (0.41) | CA1CA2LMNACA12CA3 | |
| SCHEMBL563118 | 0.91 | LMNA (0.40) | CA1CA2LMNACA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642641-B2 | Co-crystals of pyrrolidinones | UCB PHARMA, S.A. (BE) | 2014-02-04 | — | — | US | claimed |
| EP-2041084-B1 | CO-CRYSTALS OF PYRROLIDINONES | UCB PHARMA SA (BE) | 2013-11-06 | — | — | EP | claimed |
| US-20120245215-A1 | Co-Crystals of Pyrrolidinones | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | claimed |
| US-20100240728-A1 | Co-Crystals of Pyrrolidinones | UCB PHARMA, S.A. (BE) | 2010-09-23 | — | — | US | claimed |
| EP-1452524-B1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB PHARMA SA (BE) | 2009-10-14 | — | — | EP | claimed |
| CN-101506157-A | Co-crystals of pyrrolidinones | UCB PHARMA SA (BE) | 2009-08-12 | — | — | CN | claimed |
| EP-2041084-A1 | CO-CRYSTALS OF PYRROLIDINONES | UCB Pharma, S.A. (BE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007141002-A1 | CO-CRYSTALS OF PYRROLIDINONES | UCB PHARMA, S.A. (BE) | 2007-12-13 | — | — | WO | claimed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | claimed |
| EP-1452524-A1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB, S.A. (BE) | 2004-09-01 | — | — | EP | claimed |
| US-20040116507-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2004-06-17 | — | — | US | claimed |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2003-06-26 | — | — | US | claimed |
| EP-1265862-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2002-12-18 | — | — | EP | claimed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | claimed |
| CN-117466797-A | Preparation method of Brivaracetam | 重庆普佑生物医药有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117447374-A | New method for preparing brivaracetam | 重庆普佑生物医药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3302441-B1 | PROCESSES TO PRODUCE BRIVARACETAM | SUZHOU PENGXU PHARMATECH CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265862-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245215-A1 | Co-Crystals of Pyrrolidinones | PYCR1, CCNT1, PRMT1 | CA1 1299/4885CA2 2448/4885LMNA 3002/4885 |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, CYP1A2, OGDH | CA1 1842/4885CA2 1417/4885LMNA 3771/4885 |
| US-20100240728-A1 | Co-Crystals of Pyrrolidinones | PYCR1, C1S, CCNT1 | CA1 1434/4885CA2 2766/4885LMNA 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.